Author

Deborah A. Ferguson

Institutions: Biogen (United States), Reata Pharmaceuticals (United States)

Observed institutions: Biogen (United States), Beth Israel Deaconess Medical Center, The University of Texas MD Anderson Cancer Center, Harvard University, Reata Pharmaceuticals (United States), Massachusetts General Hospital, University Hospitals Cleveland Medical Center, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Colorado Anschutz, The University of Texas Southwestern Medical Center, University of Colorado Denver

OpenAlex ID: A5104110168

Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure

1998 · William T. Abraham, Brian D. Lowes, et al. · Journal of Cardiac Failure · 253

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

2012 · David S. Hong, Razelle Kurzrock, et al. · Clinical Cancer Research · 237

Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

2011 · Pablo E. Pergola, Melissa Krauth, et al. · American Journal of Nephrology · 234

Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1

2011 · Qing Qing Wu, Yanxia Wang, et al. · American Journal of Physiology-Renal Physiology · 158

RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity

2015 · Brandon L. Probst, Isaac Trevino, et al. · PLoS ONE · 104

Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405

2015 · Brandon L. Probst, Lyndsey McCauley, et al. · PLoS ONE · 70

Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding

2016 · Carlos Huerta, Xin Jiang, et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 69

Evaluating the potential of Vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide

2008 · Sylvain Lebreton, Janis Jaunbergs, et al. · Bioorganic & Medicinal Chemistry Letters · 55

The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II–induced contraction of glomerular mesangial cells

2012 · Yanfeng Ding, Rhesa D. Stidham, et al. · Kidney International · 51

Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD

2020 · James H. Lewis, Michel Jadoul, et al. · Clinical and Translational Science · 41

Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis

2020 · Scott A. Reisman, Deborah A. Ferguson, et al. · Journal of Biochemical and Molecular Toxicology · 22

Selective Identification of Secreted and Transmembrane Breast Cancer Markers using Escherichia coli Ampicillin Secretion Trap

2005 · Deborah A. Ferguson, Matthew R. Muenster, et al. · Cancer Research · 20

A novel series of cysteine-dependent, allosteric inverse agonists of the nuclear receptor RORγt

2020 · Xin Jiang, Irina Dulubova, et al. · Bioorganic & Medicinal Chemistry Letters · 16

eXPRESSION: An in silico tool to predict patterns of gene expression

2005 · Deborah A. Ferguson, Jing-Tzyh Alan Chiang, et al. · Gene Expression Patterns · 14

319: Bardoxolone Methyl (BARD) Inhibits Inflammatory Signaling in Cultured Mesangial Cells

2010 · W. Christian Wigley, Rong Ma, et al. · American Journal of Kidney Diseases · 4

205 Discovery and Development of Bardoxolone Methyl, an Antioxidant Inflammation Modulator (AIM) Targeting the KEAP1-NRF2 Pathway

2011 · Colin J. Meyer, W. Christian Wigley, et al. · American Journal of Kidney Diseases · 1

Genetic and pharmacologic inhibition of Keap1 dampens the pro-fibrotic program in human hepatic stellate cells

2026 · Sharadha Dayalan Naidu, Ralitsa R. Madsen, et al. · Scientific Reports

Supplementary Figure Legend from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

2023 · David S. Hong, Razelle Kurzrock, et al.

Supplementary Figure 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

2023 · David S. Hong, Razelle Kurzrock, et al.

Data from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

2023 · David S. Hong, Razelle Kurzrock, et al.

Supplementary Table 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

2023 · David S. Hong, Razelle Kurzrock, et al.

Supplementary Table 1 from A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

2023 · David S. Hong, Razelle Kurzrock, et al.

ChemInform Abstract: Evaluating the Potential of Vacuolar ATPase Inhibitors as Anticancer Agents and Multigram Synthesis of the Potent Salicylihalamide Analogue Saliphenylhalamide (V).

2009 · Sylvain Lebreton, Janis Jaunbergs, et al. · ChemInform

Works count: 23

Citation count: 1,349

H-index: 14

I10-index: 14